In line with this observation, Le et al. found that the immune-related objective response rate and immune-related PFS rate in anti-PD-1 antibody-treated patients with mismatch repair-deficient colorectal cancer were higher compared with patients with mismatch repair-proficient colorectal cancer [82]. Here, PDCD1 is linked to colorectal cancer.